公开(公告)号：US10903914B2

公开(公告)日：2021-01-26

申请号：US15866384

申请日：2018-01-09

Applicant: ABBOTT DIABETES CARE INC. ,  UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Inventor： Marc D. Breton ,  Boris P. Kovatchev ,  Erwin S. Budiman ,  Kenneth J. Doniger

IPC: H04B17/00 ,  A61B5/145 ,  A61B5/00 ,  A61B5/1473 ,  G06F19/00 ,  G16H40/67 ,  G16H10/40

Abstract: Method, system and computer program product for providing real time detection of analyte sensor sensitivity decline is continuous glucose monitoring systems are provided.

公开(公告)号：US20200016336A1

公开(公告)日：2020-01-16

申请号：US16483487

申请日：2018-02-05

Applicant: University of Virginia Patent Foundation

Inventor： Stephen D. Patek ,  Marc D. Breton

IPC: A61M5/172 ,  A61B5/145 ,  A61M5/142 ,  G16H10/60 ,  G16H20/17 ,  G16H40/67

Abstract: Equivalent insulin pump retrospective virtual basal rates for daily injections are constructed from planned insulin injections according to a virtual basal rate profile developed for a patient, and a database of historical insulin injections, i.e. basal injections actually administered by the patient, providing a unified framework for analysis, design, optimization, and adaptation of MDI (multiple daily injections) and CSII (continuous subcutaneous insulin infusion (i.e. insulin pump)) treatment parameters for patients with diabetes.

公开(公告)号：US10456086B2

公开(公告)日：2019-10-29

申请号：US15252365

申请日：2016-08-31

Applicant: University of Virginia Patent Foundation

Inventor： Marc D. Breton ,  Najib Ben-Brahim

IPC: G01N33/48 ,  A61B5/00 ,  A61B5/0205 ,  A61B5/145 ,  A61M5/172 ,  G16H40/67 ,  G16H50/20 ,  A61B5/11 ,  A61M5/142

Abstract: A system, method and non-transient computer readable medium for predicting hypoglycemic risk in patients with diabetes following moderate exercise. A system may include a digital processor; and an exercise module configured to generate a hypoglycemia risk signal with a hypoglycemia prediction algorithm and to determine a hypoglycemia risk state with a classifier algorithm that classifies the hypoglycemia risk signal to identify an actionable hypoglycemia risk state based on a predefined threshold.

公开(公告)号：US10438700B2

公开(公告)日：2019-10-08

申请号：US14419375

申请日：2013-08-05

Applicant: University of Virginia Patent Foundation

Inventor： Edward A. Ortiz ,  Stephen D. Patek ,  Marc D. Breton ,  Leon S. Farhi ,  Boris P. Kovatchev

IPC: G01N33/48 ,  G16H50/50 ,  C12Q1/54

Abstract: Time-varying hyperglycemic stresses are derived from actual ICU patients and applied to non-critically ill virtual patients, using any model of normal glucose-insulin physiology that fulfills certain requirements, in order to model and simulate stress hyperglycemia. Other aspects provide: 1) a methodology to perform sensitivity analyses of the parameters of ICU insulin infusion therapy protocols and to improve the protocols; and 2) a training system for clinicians about the course and management of stress hyperglycemia in the ICU or other facility.

公开(公告)号：US10169544B2

公开(公告)日：2019-01-01

申请号：US14902731

申请日：2014-07-03

Applicant: University of Virginia Patent Foundation

Inventor： Marc D. Breton ,  Boris P. Kovatchev ,  Chiara Dalla Man ,  Claudio Cobelli ,  Francesco Micheletto

IPC: G06F19/00 ,  G16H50/50

Abstract: A simulator for in-silico testing of Type 1 diabetes patients uses a model that puts in relation plasma concentrations, i.e., glucose G and insulin /, with glucose fluxes, i.e. endogenous glucose production (EGP), glucose rate of appearance (Ra), glucose utilization by the tissues (U), renal extraction (E), and insulin fluxes, i.e., rate of insulin appearance from the subcutaneous tissues (SC) and insulin degradation (D). A module is also included to describe counter-regulation, i.e. glucagon kinetics, secretion and action. A glucagon subcutaneous absorption model enables simulation of dual hormone control.

公开(公告)号：US20180055452A1

公开(公告)日：2018-03-01

申请号：US15252365

申请日：2016-08-31

Applicant: University of Virginia Patent Foundation

Inventor： Marc D. Breton

IPC: A61B5/00 ,  A61B5/0205 ,  A61B5/145 ,  A61M5/172

CPC classification number: A61B5/7275 ,  A61B5/0205 ,  A61B5/1118 ,  A61B5/14532 ,  A61B5/4839 ,  A61B5/7225 ,  A61B5/7264 ,  A61B2562/0219 ,  A61M5/1723 ,  A61M2005/14208 ,  A61M2205/3303 ,  A61M2205/3327 ,  A61M2205/35 ,  A61M2205/3561 ,  A61M2205/505 ,  A61M2205/52 ,  G16H40/67 ,  G16H50/20

Abstract: A system, method and non-transient computer readable medium for predicting hypoglycemic risk in patients with diabetes following moderate exercise. A system may include a digital processor; and an exercise module configured to generate a hypoglycemia risk signal with a hypoglycemia prediction algorithm and to determine a hypoglycemia risk state with a classifier algorithm that classifies the hypoglycemia risk signal to identify an actionable hypoglycemia risk state based on a predefined threshold.

公开(公告)号：US20160171183A1

公开(公告)日：2016-06-16

申请号：US14902731

申请日：2014-07-03

Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Inventor： Marc D. Breton ,  Boris P. Kovatchev ,  Chiara Dalla Man ,  Claudio Cobelli ,  Francesco Micheletto

IPC: G06F19/00

CPC classification number: G06F19/702 ,  G06F19/00 ,  G16H50/50

Abstract: A simulator for in-silico testing of Type 1 diabetes patients uses a model that puts in relation plasma concentrations, i.e., glucose G and insulin /, with glucose fluxes, i.e. endogenous glucose production (EGP), glucose rate of appearance (Ra), glucose utilization by the tissues (U), renal extraction (E), and insulin fluxes, i.e., rate of insulin appearance from the subcutaneous tissues (SC) and insulin degradation (D). A module is also included to describe counter-regulation, i.e. glucagon kinetics, secretion and action. A glucagon subcutaneous absorption model enables simulation of dual hormone control.

Abstract translation: 用于1型糖尿病患者电脑测试的模拟器使用将血浆浓度（即葡萄糖G和胰岛素/）与葡萄糖通量（即内源性葡萄糖产生量（EGP），外观葡萄糖率（Ra））， 通过组织（U），肾提取（E）和胰岛素通量的葡萄糖利用率，即皮下组织（SC）和胰岛素降解（D）的胰岛素出现率。 还包括一个模块来描述反调节，即胰高血糖素的动力学，分泌和作用。 胰高血糖素皮下吸收模型可以模拟双重激素控制。

公开(公告)号：US20140046159A1

公开(公告)日：2014-02-13

申请号：US14015831

申请日：2013-08-30

Applicant: University of Virginia Patent Foundation

Inventor： Boris P. Kovatchev ,  Marc D. Breton ,  Stephen D. Patek

IPC: A61B5/145 ,  A61B5/00 ,  A61M5/172

CPC classification number: A61B5/14532 ,  A61B5/0002 ,  A61B5/0004 ,  A61B5/4839 ,  A61B5/7275 ,  A61B5/746 ,  A61M5/1723 ,  G06F19/00 ,  G06F19/3418 ,  G06F19/3456 ,  G06F19/3468 ,  G16H40/63 ,  G16H50/50

Abstract: An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

Abstract translation: 本发明的实施方案或部分实施方案的一个方面（或本发明的全部或部分中的各种实施方案的组合）包括但不限于此，用于连续评估所述方法和系统（以及相关的计算机程序产品） 患者出现低血糖风险，然后根据风险评估确定采取什么行动。 进一步的实施例产生两个输出：（1）应用于发送到泵的胰岛素速率指令的衰减因子（通过常规治疗或经由开环或闭环控制）和/或（2）红/黄/ 绿灯低血糖警报为患者提供低血糖风险的指示。 CPHS的两个输出可以组合使用或单独使用。